QUIMILZA3VI Trademark

Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the treatment of generalized pustular psoriasis (GPP); Pharmaceutical preparations for the treatment of a disease or disorder that is responsive to IL-36R inhibition or neutralization, namely, a disease or disorder in which a decrease in IL-36R levels or activity has a therapeutic benefit; Pharmaceutical preparations for the treatment of a disease or disorder that is responsive to IL-36R inhibition or neutralization, namely, a disease or disorder in which the improper expression or increased activity of IL-36R causes or contributes to the pathological effects of the disease or disorder; Pharmaceutical preparations for the treatment of a disease or disorder that is responsive to IL-36R inhibition or neutralization, namely, inflammatory diseases, autoimmune diseases, respiratory diseases, metabolic disorders, and cancer; Pharmaceutical preparations for the treatment of an inflammatory disorder, namely, allergic inflammation of the skin, lungs, and gastrointestinal tract, atopic dermatitis or atopic eczema, allergic asthma and non-allergic asthma, epithelial-mediated inflammation, fibrosis, idiopathic pulmonary fibrosis, scleroderma, kidney fibrosis, scarring, allergic rhinitis, food allergies, seasonal allergies, and other allergies; Pharmaceutical preparations for the treatment of an autoimmune disease, namely, multiple sclerosis, asthma, Type 1 diabetes mellitus, rheumatoid arthritis, scleroderma, Crohn's disease, psoriasis vulgaris or psoriasis, pustular psoriasis, generalized pustular psoriasis (GPP), palmo-plantar pustulosis (PPP), inflammatory bowel disease, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, and ankylosing spondylitis; Pharmaceutical preparations for the treatment of a respiratory disease, namely, asthma, cystic fibrosis, emphysema, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome; Pharmaceutical preparations for the treatment of a metabolic disorder, namely, obesity, Type 2 diabetes, atherosclerosis, and cardiovascular disease; Pharmaceutical preparations for the treatment of cancer, namely, melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gall bladder cancer, laryngeal cancer, liver cancer, thyroid cancer, stomach cancer, salivary gland cancer, prostate cancer, pancreatic cancer, leukemia, lymphoma, and Merkel cell carcinoma; Pharmaceutical preparations for the treatment of a chronic skin condition, namely, hidradenitis suppurativa; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue